<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82433">
  <stage>Registered</stage>
  <submitdate>22/11/2007</submitdate>
  <approvaldate>28/11/2007</approvaldate>
  <actrnumber>ACTRN12607000611426</actrnumber>
  <trial_identification>
    <studytitle>Phase Ia Pharmacokinetic and Tolerability Study of Oral NV-27 in Normal Healthy Volunteers</studytitle>
    <scientifictitle>Phase Ia Pharmacokinetic and Tolerability Study of Oral NV-27 in Normal Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Safety and tolerability of the investigational drug NV-27 in healthy male volunteers</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>6 healthy male volunteers will each take 400mg of study drug NV-27 once, orally on day 1. The participants will be closely monitored for 5 days to determine the pharmacokinetics and tolerability of NV-27. Participants will then be required to return 4 weeks after taking NV-27 to assess their tolerability and the safety of NV-27.</interventions>
    <comparator>no comparator</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the pharmacokinetics of an acute dose of NV-27 administered orally.</outcome>
      <timepoint>To assess pharmacokinetics each participant will have blood collected prior to taking NV-27 and then at 10, 20, 30, 45, and 60 mins, 1.5h, 2h, 2.5h, 3h, 4h, 8h, 24h, and 72h following ingestion of NV-27.

In addition each participant will be required to collect urine prior to taking NV-27 and then collect all urine up to 96hrs following ingestion of NV-27.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the safety and tolerability of an acute dose of NV-27 administered orally.</outcome>
      <timepoint>Participants will be monitored for safety and tolerability for 5 days following NV-27 ingestion. Participants will then be required to return 4 weeks after taking NV-27 to assess their tolerability and the safety of NV-27.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>a) Normal healthy male volunteers
b) At screening, patients must have all clinical pathology analytes within the laboratorys reference ranges
c) Participants must be 18 - 40 years of age
d) Non-smokers
e) Participants must be able to understand the risks and benefits of the study and give written informed consent to participation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>a) Participants who are on a concurrent investigational drug study or who have had any treatment with any investigational agents within 4 weeks of commencing the study
b) Alcohol consumption of &gt; 40g per day
c) A history of alcohol or drug dependence within the last three years
d) A chronic illness which requires regular therapy
e) Asthma
f) Previous hypersensitivity or allergy to aspirin or other anti-inflammatory agents 
g) Use of any prescription medication within the preceding week</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>10/12/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>6</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>4215</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novogen Research Pty Ltd</primarysponsorname>
    <primarysponsoraddress>140 Wicks Road
North Ryde
NSW 2113</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novogen Research Pty Ltd</fundingname>
      <fundingaddress>140 Wicks Road
North Ryde 
NSW 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial will involve 6 healthy male volunteers to determine the pharmacokinetics and safety/tolerability of the investigational drug NV-27.</summary>
    <trialwebsite>www.novogen.com.au</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Bond University Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>13/12/2007</ethicapprovaldate>
      <hrec>RO521(1)</hrec>
      <ethicsubmitdate>21/11/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Laurie Howes</name>
      <address>Queensland Radiology
138 Queens Street
Southport 
QLD 4215</address>
      <phone>(07) 5571-8979</phone>
      <fax />
      <email>laurie_howes@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Jan Howes</name>
      <address>Queensland Radiology
138 Queens Street
Southport 
QLD 4215</address>
      <phone>(07) 5519 8859</phone>
      <fax />
      <email>menopausesolutions@aapt.net.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Tracy Jamison</name>
      <address>140 Wicks Rd
North Ryde
NSW 2113</address>
      <phone />
      <fax />
      <email>Tracy.Jamison@novogen.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>